

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 October 2022 (13.10.2022)



(10) International Publication Number
WO 2022/217265 A1

(51) International Patent Classification:

A61K 31/335 (2006.01) C07D 313/12 (2006.01)
A61K 31/357 (2006.01) A61K 31/4353 (2006.01)
C07D 313/10 (2006.01) C07D 471/04 (2006.01)

NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(21) International Application Number:

PCT/US2022/071613

(22) International Filing Date:

08 April 2022 (08.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/173,368 10 April 2021 (10.04.2021) US

(71) Applicant: SUNOVION PHARMACEUTICALS INC.
[US/US]; 84 Waterford Drive, Marlborough, MA 01752
(US).

(72) Inventors: HODGETTS, Kevin, Julian; c/o Sunovion
Pharmaceuticals Inc., 84 Waterford Drive, Marlborough,
MA 01752 (US). XIE, Linghong; c/o Sunovion Phar-
maceuticals Inc., 84 Waterford Drive, Marlborough, MA
01752 (US).

(74) Agent: SIMMONS, Rebecca, L. et al.; Hamilton, Brook,
Smith & Reynolds, P.C., 530 Virginia Rd, P.O. Box 9133,
Concord, MA 01742-9133 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: TAARI AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF



(57) Abstract: Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., R¹, R², X¹, X², Y¹, Y², Y³, Y⁴, Y⁵, Y⁶, Y⁷, and Y⁸) are as disclosed herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of using the compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions of the foregoing, e.g., to treat a neurological or psychiatric disease or disorder.



WO 2022/217265 A1